Smith & Nephew reports Chief Executive Officer Deepak Nath and three other managers bought American Depositary Shares at $31.2097 each through the Employee Stock Purchase Plan and Dividend Re-Investment Plan following the 2026 interim dividend paid on 6 November 2026.
SNN · Smith & Nephew PLC
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $29.83
- Open
- $30.02
- Day range
- $29.79–30.11
- 52-week closing range
- $26.42–36.90
- Average volume, 30 days
- 1.4M
- Short interest
- 4.4M · 1.1% of shares · 3.7 days
- Short volume, last session
- 53%
- Last earnings
- Aug 4, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Smith & Nephew plc executives purchased ordinary shares through the company’s Dividend Re-Investment Plan on 2026 – 11 – 06 at 11.676693 per share, following the 2026 interim dividend payment on 6 November 2026.
Smith+Nephew reported Q3 revenue of $1,551 million, up 3.4%, as Sports Medicine momentum offset weak US Orthopaedics. Full-year underlying revenue growth guidance fell to around 3%, trading profit growth to around 4%, and free cash flow to around $750 million.
Smith+Nephew reported $1,551 million of Q3 revenue, up 3.4%, but cut full-year underlying revenue growth guidance to around 3% from around 4% amid slower US Orthopaedics growth. Free cash flow guidance fell to around $750 million.
Smith & Nephew plc reports that as at 31 October 2026 its total issued share capital is 877,750,024 ordinary shares, including 40,315,859 held in treasury. That leaves 837,434,165 shares with one voting right each, which shareholders should use as the denominator for FCA disclosure thresholds.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SNN
this stock
Smith & Nephew PLC
|
$12.47B | -9.1% | — | — | 1.1% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 78
Smith & Nephew reports Chief Executive Officer Deepak Nath and three other managers bought American Depositary Shares at $31.2097 each through the Employee Stock Purchase Plan and Dividend Re-Investment Plan following the 2026 interim dividend paid on 6 November 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SNN | -3.8% | -3.4% | +1.2% | +0.4% | -9.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +1.7% | +2.9% | +6.8% | +5.7% | -14.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.